Jurrien M. Ten Berg
Distinguished in Heart Attack

Jurrien M. Ten Berg

Sint Antonius Ziekenhuis
Nieuwegein, UT, NL 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Heart Attack
Sint Antonius Ziekenhuis
Nieuwegein, UT, NL 
OverviewLocationsClinical Research

Overview

Jurrien Ten Berg practices in Nieuwegein, Netherlands. Mr. Ten Berg is rated as a Distinguished expert by MediFind in the treatment of Heart Attack. His top areas of expertise are Heart Attack, Acute Coronary Syndrome, Hypertrophic Cardiomyopathy (HCM), Percutaneous Coronary Intervention (PCI), and Transcatheter Aortic Valve Replacement (TAVR).

His clinical research consists of co-authoring 419 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 135 articles and participated in 4 clinical trials in the study of Heart Attack.

Gender
Male

Locations

Sint Antonius Ziekenhuis
Nieuwegein, UT, Netherlands
Other Locations
Erasmus MC
Rotterdam, ZH, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Having Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention?
What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Having Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention?
Enrollment Status: Recruiting
Publish Date: December 15, 2023
Intervention Type: Drug
Study Drug: Dual antiplatelet therapy
Study Phase: Phase 4
A Phase 3 Prospective, Blinded, Randomized, Placebo Controlled, International Multicenter Study to Assess the Safety and Efficacy of a Single SQ Injection of Zalunfiban in Subjects With ST-elevation MI in the Pre-hospital Setting
A Phase 3 Prospective, Blinded, Randomized, Placebo Controlled, International Multicenter Study to Assess the Safety and Efficacy of a Single SQ Injection of Zalunfiban in Subjects With ST-elevation MI in the Pre-hospital Setting
Enrollment Status: Active_not_recruiting
Publish Date: June 29, 2025
Intervention Type: Drug
Study Drug: zalunfiban
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)
A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Drug
Study Phase: Phase 3
Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation
Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation
Enrollment Status: Completed
Publish Date: April 30, 2020
Intervention Type: Drug
Study Phase: Phase 4
Cost-effectiveness of CYP2C19 Genotype Guided Treatment With Antiplatelet Drugs in Patients With ST-segment-elevation Myocardial Infarction Undergoing Immediate PCI With Stent Implantation: Optimization of Treatment (POPular Genetics).
Cost-effectiveness of CYP2C19 Genotype Guided Treatment With Antiplatelet Drugs in Patients With ST-segment-elevation Myocardial Infarction Undergoing Immediate PCI With Stent Implantation: Optimization of Treatment (POPular Genetics).
Enrollment Status: Completed
Publish Date: May 10, 2019
Intervention Type: Genetic
Study Phase: Phase 4
View 4 Less Clinical Trials

419 Total Publications

VARC-HBR criteria validation in TAVI patients on oral anticoagulation.
VARC-HBR criteria validation in TAVI patients on oral anticoagulation.
Journal: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Published: September 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ten Berg's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 11 Advanced Conditions
View All 19 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile